Table 1.
Baseline characteristics of the patients with and without sarcopenia
| Variable | All patients (n = 168) | Without sarcopenia (n = 102) | With sarcopeniaa (n = 66) | P‐value |
|---|---|---|---|---|
| Age (years) | 58 (51–62) | 56 (50–61) | 60 (55–63) | <0.001 |
| Weight (kg) | 71.5 ± 13.1 | 74.5 ± 10.5 | 66.8 ± 14.9 | <0.001 |
| Height (m) | 1.67 ± 0.07 | 1.68 ± 0.06 | 1.64 ± 0.07 | <0.001 |
| BMI (kg/m2) | 25.7 ± 4.2 | 26.2 ± 3.0 | 24.9 ± 5.3 | 0.04 |
| Aetiology (ischaemic/non‐ischaemic) | 48/120 | 26/76 | 22/44 | 0.30 |
| Aetiology (Chagas/no Chagas) | 40/128 | 26/76 | 14/52 | 0.58 |
| NYHA class (I/II/III/IV) | 54/57/46/11 | (39/31/24/8) | (15/26/22/3) | 0.20 |
| LVEF (%) | 27 (22–33) | 27 (22–33) | 25 (21–34) | 0.82 |
| BNP (pg/mL) | 438 (147–1050) | 363 (123–993) | 461 (154–1336) | 0.54 |
| hs‐CRP (mg/L) | 2.8 (1.0–7.1) | 2.4 (0.9–5.9) | 3.3 (1.2–12.7) | 0.049 |
| Creatinine (mg/dL) | 1.1 (1.0–1.5) | 1.2 (1.0–1.5) | 1.1 (1.0–1.4) | 0.12 |
| Sodium (mEq/L) | 140 (138–141) | 140 (138–141) | 139 (138–141) | 0.75 |
| Potassium (mEq/L) | 4.5 (4.3–4.8) | 4.5 (4.3–4.7) | 4.6 (4.3–4.9) | 0.16 |
| Haemoglobin (g/dL) | 13.9 ± 1.8 | 14.0 ± 1.8 | 14.0 ± 1.5 | 0.84 |
| Fasting glucose (mg/dL) | 104 (95–115) | 104 (95–114) | 104 (95–119) | 0.87 |
| Medication | ||||
| Beta‐blocker, n (%) | 164 (98) | 99 (97) | 65 (98) | 1.00 |
| ACE‐I/ARB, n (%) | 153 (91) | 95 (93) | 58 (88) | 0.28 |
| Thiazide/loop diuretics, n (%) | 132 (79) | 80 (78) | 52 (79) | 1.00 |
| Aspirin, n (%) | 66 (39) | 34 (33) | 32 (48) | 0.06 |
| Statins, n (%) | 91 (54) | 51 (50) | 40 (61) | 0.21 |
| MRA, n (%) | 118 (70) | 71 (70) | 47 (71) | 0.86 |
| Warfarin, n (%) | 44 (26) | 32 (31) | 12 (18) | 0.07 |
| Vasodilators, n (%) | 49 (29) | 32 (31) | 17 (26) | 0.49 |
| Metformin, n (%) | 22 (13) | 11 (11) | 11 (17) | 0.35 |
ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, B‐type natriuretic peptide; hs‐CRP, high‐sensitivity C‐reactive protein; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.
Data are presented as mean ± SD, median (with lower and upper quartiles), or frequencies and percentages.
a
Patients classified by all methods.